Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Calf Deep Vein Thrombosis Treatment Trial
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 5
- Registration Number
- NCT03590743
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic, La Crosse, Wisconsin, United States
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64684
- Registration Number
- NCT03572972
- Locations
- 🇰🇷
Korea University Hospital, Seoul, Korea, Republic of
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 64920
- Registration Number
- NCT03563937
- Locations
- 🇩🇪
Many Locations, Multiple Locations, Germany
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 1512
- Registration Number
- NCT03463317
- Locations
- 🇩🇪
Vivantes Klinik Am Urban, Kardiologie, Berlin, Germany
🇩🇪Charité Universitätsmedizin Berlin, CBF, Kardiologie, Berlin, Germany
🇩🇪Vivantes Klinikum Neukölln, Kardiologie, Berlin, Germany
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 24
- Registration Number
- NCT03456648
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Vlaams-brabant, Belgium
Bariatric Surgery and Pharmacokinetics of Apixaban
- Conditions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03448783
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51690
- Registration Number
- NCT03441633
- Locations
- 🇪🇸
IDIAP Jordi Gol, Barcelona, Cataluña, Spain
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 1300
- Registration Number
- NCT03404635
- Locations
- 🇺🇸
Eskenazi Health System, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States
Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03398434
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Portola Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT03310021
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.